Eliptica Limited
Research and experimental development on biotechnology · Newbury
ActiveUnited KingdomIncorporated 2022Private Limited Company
Documents & history
Available account evidence and business events. This is not a complete filing history or document library.
Accounts to 2025-12-31
IXBRL · 121 source facts · 10 selected values
Validation findingsXBRL valid
Accounts to 2025-12-31
IXBRL · 121 source facts · 10 selected values
Validation findings
XBRL valid
- Reporting period
- 2025-01-01 to 2025-12-31
- Extraction status
- complete
- Numeric facts
- 79
- Documents processed
- 1
- XBRL standards validation
- valid
- Filing-profile validation
- invalid
- Parser
- arelle 2.44.4
- Taxonomy
- FRS-102-2024-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod223_4312_14041502_20251231
- Source archive
- Accounts_Bulk_Data-2026-09-22.zip
Extraction findings: filing rules invalid. These describe source processing, not an audit opinion on the company.
Accounts to 2024-12-31
IXBRL · 126 source facts · 10 selected values
Validation findingsXBRL valid
Accounts to 2024-12-31
IXBRL · 126 source facts · 10 selected values
Validation findings
XBRL valid
- Reporting period
- 2024-01-01 to 2024-12-31
- Extraction status
- complete
- Numeric facts
- 85
- Documents processed
- 1
- XBRL standards validation
- valid
- Filing-profile validation
- invalid
- Parser
- arelle 2.44.4
- Taxonomy
- FRS-102-2024-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_2507_14041502_20241231
- Source archive
- Accounts_Monthly_Data-July2025.zip
Extraction findings: filing rules invalid. These describe source processing, not an audit opinion on the company.
Accounts to 2023-12-31
IXBRL · 123 source facts · 20 selected values
Not assessedlegacy record
Accounts to 2023-12-31
IXBRL · 123 source facts · 20 selected values
Not assessed
legacy record
- Reporting period
- 2023-01-01 to 2023-12-31
- Extraction status
- Legacy / not assessed
- Numeric facts
- 85
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- FRS-102-2023-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_3000_14041502_20231231
- Source archive
- Accounts_Monthly_Data-October2024.zip
Accounts to 2022-12-31
IXBRL · 80 source facts · 11 selected values
Not assessedlegacy record
Accounts to 2022-12-31
IXBRL · 80 source facts · 11 selected values
Not assessed
legacy record
- Reporting period
- 2022-04-12 to 2022-12-31
- Extraction status
- Legacy / not assessed
- Numeric facts
- 44
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- FRS-102-2021-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_0026_14041502_20221231
- Source archive
- Accounts_Monthly_Data-September2023.zip
Registered details
14041502- Status
- Active
- Type
- Private Limited Company
- Incorporated
- 2022-04-12
- Jurisdiction
- —
- Registered office
- 2, COMMUNICATIONS ROAD, NEWBURY, BERKSHIRE, RG19 6AB
Classification
1 SIC codes72110
Capital & company events
Reconstructed equity rounds and matched research funding.
Equity fundraising
2 SH01-derived rounds2023-12-20
£1,999,995 raised
£10,497,741 estimated post-money
2022-09-12
£2,000,026 raised
£6,165,549 estimated post-money
Research and innovation
2 matched grantsAIPIR - Development of an advanced AI proteomic platform to identify, track and predict host response to solid tumour immunotherapiesLeadInnovate UK · Collaborative R&D · 2024-04-01 – 2026-03-31 · with 1 other participant£664,385awarded
AIPIR - Development of an advanced AI proteomic platform to identify, track and predict host response to solid tumour immunotherapiesLead
Innovate UK · Collaborative R&D · 2024-04-01 – 2026-03-31 · with 1 other participant
£664,385
awarded
Eliptica Limitedlead£664,385
University of Edinburgh£31,950
DCAD - Developing better diagnostics for Coronary Artery Disease with novel AI-enhanced, ultra fast proteomicsLeadInnovate UK · Collaborative R&D · 2023-09-01 – 2025-08-31 · with 1 other participant£664,036awarded
DCAD - Developing better diagnostics for Coronary Artery Disease with novel AI-enhanced, ultra fast proteomicsLead
Innovate UK · Collaborative R&D · 2023-09-01 – 2025-08-31 · with 1 other participant
£664,036
awarded
Eliptica Limitedlead£664,036